Insights on Clinical Trials

  1. Top 5 Challenges In Psoriasis Trials (And How To Overcome Them) 10/15/2025

    Psoriasis trials face recruitment, endpoint, regulatory, and operational challenges. Identifying common hurdles early helps sponsors streamline processes, avoid setbacks, and prevent costly delays.

  2. Rare Neurological Disease Trials: Natural History, External Controls, And RWE 10/15/2025

    Rare neurological trials face ethical and operational barriers. Natural history studies and external control arms provide accepted, practical alternatives to de-risk development and accelerate patient access.

  3. What Can The Tech Sector's 'Minimally Viable' Concept Teach Biopharma? 10/9/2025

    Deciding what is good enough to get started can support the mindset of building something without sacrificing quality, functionality, or safety.

  4. Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems 10/7/2025

    Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.

  5. Rescuing A Global Full-Service Phase III Trial For A Late-Stage Oncology Biotech 10/2/2025

    This case underscores the expertise employed in a comprehensive strategy and set of services that were used to salvage a Phase III clinical trial for ovarian cancer and ensure its timely completion.

  6. Precision Medicine: Targeted Cancer Therapies 10/2/2025

    Cancer research is entering a new precision-driven era, with targeted therapies focusing on the specific genetic or molecular mechanisms that fuel tumor growth.

  7. Specialized Site Network For Early-Phase Oncology Success 10/2/2025

    Early-phase oncology trials are complex, demanding precision, rapid execution, and specialized expertise. Yet, too often, the operational burden falls on clinical sites―already overworked and stretched thin. Within large, volume-driven CRO networks, this creates a system that prioritizes scale over quality, offering minimal site support, delaying timelines, and ultimately compromising trial outcomes.

  8. Working With A Specialty Oncology CRO Versus A Large Generalist CRO 10/2/2025

    Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

  9. Key Takeaways From ADCs In Oncology Trials Webinar 10/2/2025

    By aligning cutting-edge design with evolving regulatory expectations, sponsors can unlock the full therapeutic potential of ADCs and deliver transformative cancer treatments to patients worldwide.

  10. BlueRock Advances Cell Therapy For Parkinson's Disease 9/30/2025

    BlueRock Therapeutics has advanced its allogeneic stem cell-derived therapy bemdaneprocel into the pivotal Phase III trial for Parkinson’s disease, aiming to restore regulated dopamine signaling, improve quality of life, and potentially transform the treatment paradigm.